Log in

OTCMKTS:RLMD - Relmada Therapeutics Stock Price, Forecast & News

+0.99 (+3.01 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
Now: $33.83
50-Day Range
MA: $40.88
52-Week Range
Now: $33.83
Volume58,794 shs
Average Volume157,950 shs
Market Capitalization$496.42 million
P/E RatioN/A
Dividend YieldN/A
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Read More

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:RLMD



Sales & Book Value

Annual SalesN/A



Market Cap$496.42 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

Relmada Therapeutics (OTCMKTS:RLMD) Frequently Asked Questions

How has Relmada Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RLMD shares have decreased by 15.8% and is now trading at $33.83. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Relmada Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Relmada Therapeutics.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics Inc (OTCMKTS:RLMD) posted its earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter. View Relmada Therapeutics' earnings history.

What price target have analysts set for RLMD?

2 equities research analysts have issued 12-month price objectives for Relmada Therapeutics' stock. Their forecasts range from $64.00 to $75.00. On average, they anticipate Relmada Therapeutics' stock price to reach $69.50 in the next twelve months. This suggests a possible upside of 105.4% from the stock's current price. View analysts' price targets for Relmada Therapeutics.

Has Relmada Therapeutics been receiving favorable news coverage?

Media stories about RLMD stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Relmada Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutRelmada Therapeutics.

What other stocks do shareholders of Relmada Therapeutics own?

Who are Relmada Therapeutics' key executives?

Relmada Therapeutics' management team includes the following people:
  • Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO, Interim CFO & Director (Age 59)
  • Dr. Ottavio V. Vitolo M.D., Sr. VP, Head of R&D and Chief Medical Officer (Age 46)
  • Mr. Michael D. Becker, Consultant (Age 50)
  • Dr. Richard M. Mangano, Consultant (Age 69)
  • Ms. Gina DiGuglielmo, VP & Head of Clinical Operations

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD."

Who are Relmada Therapeutics' major shareholders?

Relmada Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (8.86%), RA Capital Management L.P. (5.19%), Parsons Capital Management Inc. RI (2.68%), Boxer Capital LLC (2.04%), Tiedemann Advisors LLC (1.93%) and Franklin Resources Inc. (1.53%). View institutional ownership trends for Relmada Therapeutics.

Which major investors are buying Relmada Therapeutics stock?

RLMD stock was acquired by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, RA Capital Management L.P., Parsons Capital Management Inc. RI, Boxer Capital LLC, Tiedemann Advisors LLC, Franklin Resources Inc., Broadfin Capital LLC, and Point72 Asset Management L.P.. View insider buying and selling activity for Relmada Therapeutics.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $33.83.

How big of a company is Relmada Therapeutics?

Relmada Therapeutics has a market capitalization of $496.42 million. Relmada Therapeutics employs 3 workers across the globe. View additional information about Relmada Therapeutics.

MarketBeat Community Rating for Relmada Therapeutics (OTCMKTS RLMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote "Outperform" if you believe RLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel